Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FM101 in Adults With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis
NCT04710524Phase 2Unknown
- Sponsor
- Future Medicine
- Start
- Jun 2021
- Primary completion
- May 2023
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 3
01
Overview
A Phase 2 trial of FM101 in non-alcoholic fatty liver disease (NAFLD), Nonalcoholic steatohepatitis (NASH), sponsored by Future Medicine. Status: unknown.
02
Drugs
FM101
03
Conditions
non-alcoholic fatty liver disease (NAFLD)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04710524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04710524.